Abstracts tagged "osteoporosis and risk assessment"

Abstract Number: 1227 • 2017 ACR/ARHP Annual Meeting
Osteoporosis and Breast Cancer: Can FRAX-Based Risk Factors Accurately Predict Further Fractures at This Setting?
Salvador López-Salguero¹, Laura Ranieri², Juan Carlos Ordoñez³, Mariano Andrés^4,5, Jose Ponce⁶ and Isabel Ibero², ¹Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, ²Reumatología, Dpt. Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ³RHEUMATOLOGY, Dpt. Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ⁴Dpt. Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ⁵Universidad Miguel Hernández, Elche, Spain, ⁶Oncología, Dpt. Oncology, Hospital General Universitario Alicante, Alicante, Spain
Background/Purpose: Women with breast cáncer (BC) are at risk for the development of bone loss and osteoporosis (OP) mainly due to adjuvant therapies, as aromatase…
Abstract Number: 2233 • 2015 ACR/ARHP Annual Meeting
Predictors of Imminent Fracture Risk in Women Aged >=65 Years with Osteoporosis
Derek Weycker¹, Richard Barron², Alex Kartashov¹, John Edelsberg¹, DB Crittenden³ and A Grauer³, ¹Policy Analysis Inc. (PAI), Brookline, MA, ²Amgen, Inc., Thousand Oaks, CA, ³Amgen Inc., Thousand Oaks, CA
Background/Purpose: Fractures are the major source of morbidity among women with osteoporosis. However, evidence on factors leading to imminent risk for hip or other non-vertebral…
Abstract Number: 825 • 2012 ACR/ARHP Annual Meeting
Osteoporosis and Vertebral Fractures Are Important Determinants of Cardiovascular Disease in Rheumatoid Arthritis
Ausaf Mohammad¹, Derek Lohan², Diane Bergin², Sarah Mooney², John Newell³, Martin O'Donnell⁴, Robert J. Coughlan¹ and John J. Carey¹, ¹Rheumatology, Galway University Hospitals, Galway, Ireland, ²Radiology, Galway University Hospitals, Galway, Ireland, ³Clinical Research Facility, National University of Ireland, Galway, Ireland, ⁴Clinical Research Facility, Galway University Hospitals, Galway, Ireland
Background/Purpose: Cardiovascular disease(CVD) represents a major comorbidity and the leading cause of mortality for Rheumatoid arthritis(RA) patients. Unfortunately traditional risk factors for CVD underperform in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].